Thermo Fisher Scientific Inc. has signed a definitive agreement with BD (Becton, Dickinson and Company) under which Thermo Fisher will acquire BD’s advanced bioprocessing business. This business combines a strong technical services program with a variety of peptones that enhance cell culture media formulations to improve yield and reduce variability in biopharmaceutical applications. Thermo Fisher has a trusted value proposition for customers who are working in biologic drug development and manufacturing and the addition of these new capabilities will complement their bioproduction offering and strengthen the ability to serve this rapidly growing market, from development to large-scale production. BD’s advanced bioprocessing business has annualized revenue of approximately USD 100 million and will be integrated into Thermo Fisher›s life sciences solutions segment. The transaction is subject to customary closing conditions and is expected to close in early 2019.